Abstract
The peptide growth factors IGF-I and IGF-II not only play a role in the development of the mammary gland but are also implicated in breast cancer. Several reagents disrupting IGF signaling have been developed and clinical trials validating IGF signaling as a target in cancer therapy are underway. This review highlights the approaches to inhibiting IGF signaling in breast cancer.
MeSH terms
-
Antibodies, Neoplasm / therapeutic use
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / immunology
-
Breast Neoplasms / metabolism
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptor, IGF Type 1 / antagonists & inhibitors*
-
Receptor, IGF Type 1 / immunology
-
Receptor, IGF Type 1 / metabolism
-
Signal Transduction / drug effects
Substances
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Receptor, IGF Type 1